Patents by Inventor John Deadman

John Deadman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110312875
    Abstract: The present invention provides a compound of formula I, II, III and IV as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.
    Type: Application
    Filed: August 2, 2011
    Publication date: December 22, 2011
    Applicant: UNIVERSITY OF WOLLONGONG
    Inventors: Timothy Patrick Boyle, John Barnard Bremner, Zinka Brkic, Jonathan Alan Victor Coates, Neal Kevin Dalton, John Deadman, Paul Anthony Keller, Jody Morgan, Stephen Geoffrey Pyne, David Ian Rhodes, Mark James Robertson
  • Publication number: 20080300287
    Abstract: The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.
    Type: Application
    Filed: September 21, 2005
    Publication date: December 4, 2008
    Applicant: UNIVERSITY OF WOLLONGONG
    Inventors: Timothy Patrick Boyle, John Barnard Bremner, Zinka Brkic, Jonathan Alan Victor Coates, Neal Kevin Dalton, John Deadman, Paul Anthony Keller, Jody Morgan, Stephen Geoffrey Pyne, David Ian Rhodes, Mark James Robertson
  • Publication number: 20060229257
    Abstract: Salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug. Examples of such metals are calcium, magnesium and zinc. The organoboronic acid drug may be a boropeptide protease inhibitor. The salts may be formulated in oral dosage form.
    Type: Application
    Filed: May 22, 2006
    Publication date: October 12, 2006
    Inventors: John Deadman, David Madge, Mark Dolman, Sanjay Kakkar, Anthony Kennedy, Sophie Combe-Marzelle, Suresh Chahwala, Oliver Vimpany Boucher
  • Publication number: 20060172920
    Abstract: The use of a lipid in oxidised form for the manufacture of a medicament for therapeutically neutralising (i.e. reducing or substantially destroying the activity of) an organoboronate drug. The lipid may be an HDL hydroperoxide. The drug may be TRI 50c or a salt or prodrug thereof.
    Type: Application
    Filed: November 30, 2005
    Publication date: August 3, 2006
    Inventors: Michael Scully, Christopher Goodwin, John Deadman
  • Publication number: 20050288253
    Abstract: Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound.
    Type: Application
    Filed: September 9, 2003
    Publication date: December 29, 2005
    Inventors: David Madge, Mark Dolman, John Deadman, Anthony Kennedy, Sophie Combe-Marzelle, Sanjay Kakkar
  • Publication number: 20050176651
    Abstract: Tripeptide boronic acids of (R,S,R) configuration, for example Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2, and their use to make base addition salts of such acids. The salts are formulated into anti-thrombotic pharmaceutical formulations.
    Type: Application
    Filed: September 8, 2004
    Publication date: August 11, 2005
    Inventors: David Madge, Mark Dolman, Armin Walter, Dieter Krimmer, John Deadman, Alfred Olbrich, Andrea Weiland-Waibel